606 related articles for article (PubMed ID: 29926311)
21. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
[TBL] [Abstract][Full Text] [Related]
22. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG
Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044
[TBL] [Abstract][Full Text] [Related]
23. Andexanet alfa for the treatment of hemorrhage.
Cervi A; Crowther M
Expert Rev Hematol; 2018 Nov; 11(11):847-855. PubMed ID: 30296870
[TBL] [Abstract][Full Text] [Related]
24. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
25. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
Sartori M; Cosmi B
J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
[TBL] [Abstract][Full Text] [Related]
26. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
27. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic Reversal of Direct Oral Anticoagulants.
Farina N; Miller JT
Crit Care Nurs Q; 2018; 41(2):121-128. PubMed ID: 29494368
[TBL] [Abstract][Full Text] [Related]
29. Dose-Related Effectiveness of Andexanet Alfa for Reversal of Apixaban Anticoagulation in a Porcine Polytrauma Model.
Rayatdoost F; Braunschweig T; Schöchl H; Rossaint R; Grottke O
Thromb Haemost; 2024 Jan; 124(1):20-31. PubMed ID: 37604188
[TBL] [Abstract][Full Text] [Related]
30. Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report.
Flaherty D; Connors JM; Singh S; Sylvester KW; Rimsans J; Cornella L
A A Pract; 2019 Oct; 13(7):271-273. PubMed ID: 31265446
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
32. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Pollack CV
Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
[No Abstract] [Full Text] [Related]
33. Management of bleeding in patients receiving non-vitamin K antagonists.
Balla S; Koerber S; Flaker G
Postgrad Med J; 2017 Apr; 93(1098):221-225. PubMed ID: 27986971
[TBL] [Abstract][Full Text] [Related]
34. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Darius H
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
[TBL] [Abstract][Full Text] [Related]
35. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
[TBL] [Abstract][Full Text] [Related]
36. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
37. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
[TBL] [Abstract][Full Text] [Related]
38. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
39. Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA.
Heo YA
Drugs Ther Perspect; 2018; 34(11):507-512. PubMed ID: 30459509
[TBL] [Abstract][Full Text] [Related]
40. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Levy JH
Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
